These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8361441)

  • 1. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor VIII, factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
    Bejrachandra S; Chandanayingyong D; Visudhiphan S; Tumliang S; Kaewkamol K; Siribunrit U
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():162-4. PubMed ID: 7886562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 4. Coagulation factors of the newborn and his mother.
    Biland L; Duckert F
    Thromb Diath Haemorrh; 1973 Jun; 29(3):644-51. PubMed ID: 4761831
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of the KC10 semi-automatic modular clot detection device].
    Crespo B; Ankri A; Lesty C
    Nouv Rev Fr Hematol (1978); 1983; 25(2):113-21. PubMed ID: 6408609
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors.
    Lee LC; Spittell JA; Sauer WG; Owen CA; Thompson JH
    Gastroenterology; 1968 Jan; 54(1):76-85. PubMed ID: 5638294
    [No Abstract]   [Full Text] [Related]  

  • 8. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Measurements of the activity of the coagulation factors VIII:C, IX,XI, and XII in cats].
    Mischke R; Deniz A; Nolte I
    Zentralbl Veterinarmed A; 1995 Oct; 42(8):513-20. PubMed ID: 8592897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improvement in anti-hemophilic preparations and its problems. 2. Inadequacy of the heat treatment of factor concentrates on the inactivation of non-A, non-B hepatitis virus].
    Inagaki M; Osano M
    Rinsho Ketsueki; 1988 May; 29(5):635-9. PubMed ID: 3145994
    [No Abstract]   [Full Text] [Related]  

  • 11. Clotting factor concentrates in clinical practice. Standardization and assay.
    Barrowcliffe TW
    Semin Thromb Hemost; 1993; 19(1):73-9. PubMed ID: 8456326
    [No Abstract]   [Full Text] [Related]  

  • 12. Chromogenic assays for equine coagulation factors VII, VIII:C, IX, and X, and C1-esterase inhibitor.
    Topper MJ; Prasse KW
    Am J Vet Res; 1998 May; 59(5):538-41. PubMed ID: 9582952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
    Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
    Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood coagulation in hyperthermia].
    Zwierzina WD; Herold M; Günther R; Kunz F
    Z Rheumatol; 1980; 39(11-12):368-78. PubMed ID: 7282101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of TT virus DNA in plasma-derived clotting factor concentrates.
    Yokozaki S; Fukuda Y; Nakano I; Katano Y; Toyoda H; Takamatsu J
    Blood; 1999 Nov; 94(10):3617. PubMed ID: 10610120
    [No Abstract]   [Full Text] [Related]  

  • 16. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
    Hilfenhaus J; Weidmann E
    Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
    Yoshioka A; Nakagawa O; Uehara Y; Sakai T; Sugimoto M; Takamiya O; Tanaka I; Fukui H
    Thromb Res; 1987 Aug; 47(4):449-58. PubMed ID: 2958958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of non-U.S. hemophilia treatment centers for HIV seroconversions following therapy with heat-treated factor concentrates.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1987 Mar; 36(9):121-4. PubMed ID: 3102937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.